Antibody Production

摘要

Almost all of the therapeutic monoclonal antibodies produced today are produced in mammalian cells (e.g., Chinese hamster ovary [CHO] cells). This process has several drawbacks. It is expensive, time consuming, and difficult to scale up. Yet even with all of these shortcomings, it is the predominant process, mainly because it was the first. "The mammalian cell technology got there first, and that's basically the standard," says Andrew Hiatt, chief science officer at Mapp Biopharma-ceutical. "The mammalian technology is entrenched. It's successful, there are products that are selling, billions of dollars worth of antibody drugs are being produced in these huge mammalian cell fermentation facilities."